Trinity Biotech plc
TRIB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.07 | 0.00 | -1.50 |
| FCF Yield | -18.04% | -15.02% | -4.13% | 3.04% |
| EV / EBITDA | -10.33 | -6.06 | -13.92 | 21.02 |
| Quality | ||||
| ROIC | -29.18% | -58.31% | -20.01% | 3.65% |
| Gross Margin | 34.83% | 34.22% | 35.26% | 41.23% |
| Cash Conversion Ratio | 0.13 | 0.48 | 0.02 | 15.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.52% | -11.20% | -15.05% | -3.55% |
| Free Cash Flow Growth | -15.33% | -79.18% | -251.70% | -66.46% |
| Safety | ||||
| Net Debt / EBITDA | -5.65 | -2.64 | -3.93 | 6.92 |
| Interest Coverage | -2.21 | -2.67 | -0.62 | 0.55 |
| Efficiency | ||||
| Inventory Turnover | 2.07 | 1.88 | 2.34 | 1.88 |
| Cash Conversion Cycle | 200.71 | 242.63 | 204.20 | 219.35 |